This review highlights that ACE-inhibition in heart failure provides benefits beyond vasodilation by attenuating neuroendocrine activity and preventing adverse myocardial remodeling.
No takes yet. Share an insight, caveat, or question.
Broadens RAS blockade rationale in HF beyond hemodynamics; leaves open whether targeting neuroendocrine or gene effects improves outcomes.
J. Holtz (1993) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: